Randomized phase 2/3 trial of CpG oligodeoxynucleotide PF-3512676 alone or with dacarbazine for patients with unresectable stage III and IV melanoma - PubMed (original) (raw)
Clinical Trial
. 2009 Sep 1;115(17):3944-54.
doi: 10.1002/cncr.24473.
Affiliations
- PMID: 19536884
- DOI: 10.1002/cncr.24473
Free article
Clinical Trial
Randomized phase 2/3 trial of CpG oligodeoxynucleotide PF-3512676 alone or with dacarbazine for patients with unresectable stage III and IV melanoma
Jeffrey S Weber et al. Cancer. 2009.
Free article
Abstract
Background: The primary objective of this phase 2 study was to assess the objective response rate (complete response [CR] + partial responses [PR]), by Response Evaluation Criteria in Solid Tumors, of PF-3512676, a CpG oligodeoxynucleotide, alone in 2 doses or in combination with dacarbazine (DTIC) in patients with unresectable stage IIIB/C or stage IV malignant melanoma, with the aim of selecting an arm to take forward to a phase 3 portion of the study.
Methods: A total of 184 patients were randomized to 1 of 4 treatments: PF-3512676 10 mg (low dose), at 40 mg (high dose), 40 mg plus DTIC (850 mg/m(2)), or DTIC (850 mg/m(2)) alone. Patients received PF-3512676 subcutaneously weekly in a 3-week cycle and received DTIC intravenously on the first week of the cycle.
Results: The objective response rate (PR or CR, confirmed or unconfirmed) in the 40 mg + DTIC arm was 16% (7 patients) compared with 8% (3 patients) with DTIC alone. One (2%) patient in the 10-mg and 0 patients in the 40-mg arms achieved an objective response. Best response of CR or PR or stable disease (SD), with no minimum duration defined for SD, was achieved by 15 (33%) patients in the 40 mg + DTIC arm, 15 (38%) patients in the DTIC-only arm, 8 (17%) patients in the 10-mg arm, and 9 (20%) patients in the 40-mg arm. The most frequently reported adverse events were classified as local injection site reactions or systemic flu-like symptoms, specifically fatigue, rigors, and pyrexia.
Conclusions: PF-3512676 at the doses used was generally well tolerated. The modest objective response rates observed in all arms did not warrant continuation to the phase 3 portion of the study.
Similar articles
- Dacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG).
Hauschild A, Garbe C, Stolz W, Ellwanger U, Seiter S, Dummer R, Ugurel S, Sebastian G, Nashan D, Linse R, Achtelik W, Mohr P, Kaufmann R, Fey M, Ulrich J, Tilgen W. Hauschild A, et al. Br J Cancer. 2001 Apr 20;84(8):1036-42. doi: 10.1054/bjoc.2001.1731. Br J Cancer. 2001. PMID: 11308250 Free PMC article. Clinical Trial. - Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview.
Serrone L, Zeuli M, Sega FM, Cognetti F. Serrone L, et al. J Exp Clin Cancer Res. 2000 Mar;19(1):21-34. J Exp Clin Cancer Res. 2000. PMID: 10840932 - Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study.
Avril MF, Aamdal S, Grob JJ, Hauschild A, Mohr P, Bonerandi JJ, Weichenthal M, Neuber K, Bieber T, Gilde K, Guillem Porta V, Fra J, Bonneterre J, Saïag P, Kamanabrou D, Pehamberger H, Sufliarsky J, Gonzalez Larriba JL, Scherrer A, Menu Y. Avril MF, et al. J Clin Oncol. 2004 Mar 15;22(6):1118-25. doi: 10.1200/JCO.2004.04.165. J Clin Oncol. 2004. PMID: 15020614 Clinical Trial. - [Chemotherapy of malignant melanoma--current status].
Karg C, Garbe C, Orfanos CE. Karg C, et al. Hautarzt. 1990 Feb;41(2):56-65. Hautarzt. 1990. PMID: 2180855 Review. German. - Treatments for metastatic melanoma: synthesis of evidence from randomized trials.
Lui P, Cashin R, Machado M, Hemels M, Corey-Lisle PK, Einarson TR. Lui P, et al. Cancer Treat Rev. 2007 Dec;33(8):665-80. doi: 10.1016/j.ctrv.2007.06.004. Epub 2007 Oct 4. Cancer Treat Rev. 2007. PMID: 17919823 Review.
Cited by
- Intratumorally CpG immunotherapy with carbon nanotubes inhibits local tumor growth and liver metastasis by suppressing the epithelial-mesenchymal transition of colon cancer cells.
Jin H, Gao S, Song D, Liu Y, Chen X. Jin H, et al. Anticancer Drugs. 2021 Mar 1;32(3):278-285. doi: 10.1097/CAD.0000000000001000. Anticancer Drugs. 2021. PMID: 32976213 Free PMC article. - Intracerebral CpG immunotherapy with carbon nanotubes abrogates growth of subcutaneous melanomas in mice.
Fan H, Zhang I, Chen X, Zhang L, Wang H, Da Fonseca A, Manuel ER, Diamond DJ, Raubitschek A, Badie B. Fan H, et al. Clin Cancer Res. 2012 Oct 15;18(20):5628-38. doi: 10.1158/1078-0432.CCR-12-1911. Epub 2012 Aug 17. Clin Cancer Res. 2012. PMID: 22904105 Free PMC article. - Class A CpG oligodeoxynucleotide inhibits IFN-γ-induced signaling and apoptosis in lung cancer.
Teranishi S, Kobayashi N, Katakura S, Kamimaki C, Kubo S, Shibata Y, Yamamoto M, Kudo M, Piao H, Kaneko T. Teranishi S, et al. Thorac Cancer. 2020 Apr;11(4):983-992. doi: 10.1111/1759-7714.13351. Epub 2020 Feb 17. Thorac Cancer. 2020. PMID: 32067413 Free PMC article. - Anti-tumour strategies aiming to target tumour-associated macrophages.
Tang X, Mo C, Wang Y, Wei D, Xiao H. Tang X, et al. Immunology. 2013 Feb;138(2):93-104. doi: 10.1111/imm.12023. Immunology. 2013. PMID: 23113570 Free PMC article. Review. - Immunosuppressive CD14+HLA-DR(low)/- monocytes in B-cell non-Hodgkin lymphoma.
Lin Y, Gustafson MP, Bulur PA, Gastineau DA, Witzig TE, Dietz AB. Lin Y, et al. Blood. 2011 Jan 20;117(3):872-81. doi: 10.1182/blood-2010-05-283820. Epub 2010 Nov 9. Blood. 2011. PMID: 21063024 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials